According to the NCCN guidelines (Version 1.2021) [96], germline molecular testing is recommended for men with any one of the following: family history of a relative with a germline mutation, metastatic prostate cancer, regional or node-positive disease, high-risk prostate cancer (defined by grade group, T staging, and PSA levels at diagnosis), intraductal or cribriform histology, and Ashkenazi Jewish ancestry. This evidence concerns the gene KLK3 and prostate cancer.